Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

Juergen Wolf; Takashi Seto; Ji-Youn Han; Noemi Reguart; Edward B. Garon; Harry J. M. Groen; Daniel Shao-Weng Tan; Toyoaki Hida; Maja J. De Jonge; Sergey V. Orlov; Egbert F. Smit; Pierre Jean Souquet; Johan F. Vansteenkiste; Monica Giovannini; Sylvie Le Mouhaer; Anna Robeva; Maeve Waldron-Lynch; Rebecca Suk Heist

Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.

Juergen Wolf, Takashi Seto, Ji-Youn Han, Noemi Reguart, Edward B. Garon, Harry J. M. Groen, Daniel Shao-Weng Tan, Toyoaki Hida, Maja J. De Jonge, Sergey V. Orlov, Egbert F. Smit, Pierre Jean Souquet, Johan F. Vansteenkiste, Monica Giovannini, Sylvie Le Mouhaer, Anna Robeva, Maeve Waldron-Lynch, Rebecca Suk Heist

Onderzoeksoutput › Academic

Originele taal-2	English
Aantal pagina's	2
Tijdschrift	Journal of Clinical Oncology
Volume	37
Nummer van het tijdschrift	15
Status	Published - 20-mei-2019
Evenement	Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) - Chicago, Israel Duur: 31-mei-2019 → 4-jun.-2019

Handle.net

Permanente koppeling

Citeer dit

Wolf, J., Seto, T., Han, J-Y., Reguart, N., Garon, E. B., Groen, H. J. M., Tan, D. S-W., Hida, T., De Jonge, M. J., Orlov, S. V., Smit, E. F., Souquet, P. J., Vansteenkiste, J. F., Giovannini, M., Le Mouhaer, S., Robeva, A., Waldron-Lynch, M., & Heist, R. S. (2019). Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study. Journal of Clinical Oncology, 37(15).

@article{3b02bd637d044e6ab9800562b87eac7e,

title = "Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.",

author = "Juergen Wolf and Takashi Seto and Ji-Youn Han and Noemi Reguart and Garon, {Edward B.} and Groen, {Harry J. M.} and Tan, {Daniel Shao-Weng} and Toyoaki Hida and {De Jonge}, {Maja J.} and Orlov, {Sergey V.} and Smit, {Egbert F.} and Souquet, {Pierre Jean} and Vansteenkiste, {Johan F.} and Monica Giovannini and {Le Mouhaer}, Sylvie and Anna Robeva and Maeve Waldron-Lynch and Heist, {Rebecca Suk}",

year = "2019",

month = may,

day = "20",

language = "English",

volume = "37",

journal = "Journal of Clinical Oncology",

issn = "0732-183X",

publisher = "AMER SOC CLINICAL ONCOLOGY",

number = "15",

note = "Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) ; Conference date: 31-05-2019 Through 04-06-2019",

}

Wolf, J, Seto, T, Han, J-Y, Reguart, N, Garon, EB, Groen, HJM, Tan, DS-W, Hida, T, De Jonge, MJ, Orlov, SV, Smit, EF, Souquet, PJ, Vansteenkiste, JF, Giovannini, M, Le Mouhaer, S, Robeva, A, Waldron-Lynch, M & Heist, RS 2019, 'Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC): Efficacy data from the phase II GEOMETRY mono-1 study.', Journal of Clinical Oncology, vol. 37, nr. 15.

TY - JOUR

T1 - Capmatinib (INC280) in MET Delta exI4-mutated advanced non-small cell lung cancer (NSCLC)

T2 - Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO)

AU - Wolf, Juergen

AU - Seto, Takashi

AU - Han, Ji-Youn

AU - Reguart, Noemi

AU - Garon, Edward B.

AU - Groen, Harry J. M.

AU - Tan, Daniel Shao-Weng

AU - Hida, Toyoaki

AU - De Jonge, Maja J.

AU - Orlov, Sergey V.

AU - Smit, Egbert F.

AU - Souquet, Pierre Jean

AU - Vansteenkiste, Johan F.

AU - Giovannini, Monica

AU - Le Mouhaer, Sylvie

AU - Robeva, Anna

AU - Waldron-Lynch, Maeve

AU - Heist, Rebecca Suk

PY - 2019/5/20

Y1 - 2019/5/20

M3 - Meeting Abstract

VL - 37

JO - Journal of Clinical Oncology

JF - Journal of Clinical Oncology

SN - 0732-183X

IS - 15

Y2 - 31 May 2019 through 4 June 2019

ER -